BTMD
Neutral signalScored 2026-08-14 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
biote Corp.
- Nom
- biote Corp.
- Secteur
- Healthcare
- Industrie
- Medical - Care Facilities
- Bourse
- NASDAQ
- Capitalisation
- $47.4M
- Employés
- 223
- PDG
- Robert C. Peterson
- Site web
- https://biote.com
- Marché
- ABOSACTUANIKINOJYNTLUCD
Biote Corp. is dedicated to supporting and developing medical practices that focus on hormone optimization. The company provides a comprehensive system for its Biote-certified healthcare professionals, enabling them to correct imbalances in patients' hormone, vitamin, and mineral levels. This includes authorizing the prescription of bioidentical hormone treatments and suggesting suitable dietary supplements. Furthermore, Biote offers its own line of branded nutritional supplements and supplies sterile kits for inserting hormone pellets for both male and female individuals. Founded in 2011, Biote Corp. is based in Irvine, Texas.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 131 950 titres (~202 203,50 $ US)
- Insiders
- Beer Marc D
- Total bought
-
$202,204
Avg buy (VWAP, 90d window) $1.53 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-11
- Last synced
-
2026-08-21 23:36:53
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-11 | Beer Marc D | Buy · P | 16,000 | $1.55 | $24,800 | Form 4 |
| 2026-08-10 | Beer Marc D | Buy · P | 115,950 | $1.53 | $177,404 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-08-14 Drivers: fundamentals. Moteurs : fondamentaux.
BTMD shows a genuine operational turnaround with improving margins and strong FCF generation, supported by a meaningful insider cluster buy of 131,950 shares — a classically bullish event-driven signal.
The first sentence of the analysis written for BTMD on 2026-08-14 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 1.22 · operating margin 18%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 71.5% | 70.5% | 68.8% | 66.9% | 65.0% | |
| Ebit Margin | 25.3% | 6.1% | 20.9% | 3.5% | 24.8% | |
| Ebitda Margin | 27.2% | 7.9% | 21.3% | 4.8% | 25.8% | |
| Operating Profit Margin | 18.5% | 16.0% | 15.5% | -36.8% | 24.8% | |
| Pretax Profit Margin | 19.6% | 0.5% | -0.1% | 1.0% | 23.6% | |
| Continuous Operations Profit Margin | 16.4% | 0.0% | -1.5% | 0.8% | 23.4% | |
| Net Profit Margin | 14.1% | 1.6% | 1.8% | -0.6% | 23.4% | |
| Bottom Line Profit Margin | 14.1% | 1.6% | 1.8% | -0.6% | 23.4% | |
| Current Ratio | 1.215 | 1.322 | 5.507 | 5.392 | 2.720 | |
| Quick Ratio | 0.791 | 1.034 | 4.728 | 4.796 | 2.164 | |
| Solvency Ratio | 0.194 | 0.030 | 0.021 | 0.007 | 0.678 | |
| Cash Ratio | 0.536 | 0.764 | 4.006 | 4.222 | 1.546 | |
| Price To Earnings Ratio | 3.023 | 67.101 | 38.000 | -31.083 | 2.274 | |
| Price To Earnings Growth Ratio | 0.004 | -2.302 | -0.182 | 0.302 | 0.190 | |
| Forward Price To Earnings Growth Ratio | 0.004 | -2.302 | -0.182 | 0.302 | 0.190 | |
| Price To Earnings Diluted Ratio | 3.514 | 67.101 | 38.000 | -31.083 | 2.274 | |
| Price To Earnings Diluted Growth Ratio | 0.005 | -2.302 | -0.182 | 0.302 | 0.190 | |
| Price To Book Ratio | -1.389 | -1.999 | -4.320 | -0.676 | 17.995 | |
| Price To Sales Ratio | 0.423 | 1.074 | 0.685 | 0.182 | 0.532 | |
| Price To Free Cash Flow Ratio | 2.695 | 5.457 | 5.255 | -2.734 | 2.481 | |
| Price To Operating Cash Flow Ratio | 2.311 | 4.681 | 4.724 | -3.283 | 2.201 | |
| Debt To Assets Ratio | 1.021 | 0.906 | 0.740 | 1.079 | 0.687 | |
| Debt To Equity Ratio | -1.878 | -1.047 | -3.908 | -2.709 | 9.052 | |
| Debt To Capital Ratio | 2.139 | 22.469 | 1.344 | 1.585 | 0.901 | |
| Long Term Debt To Capital Ratio | 2.386 | -21.400 | 1.381 | 1.657 | 0.886 | |
| Financial Leverage Ratio | -1.838 | -1.155 | -5.283 | -2.511 | 13.171 | |
| Working Capital Turnover Ratio | 14.622 | 3.378 | 2.031 | 2.941 | 6.076 | |
| Operating Cash Flow Ratio | 0.782 | 0.878 | 1.210 | -0.488 | 1.948 | |
| Operating Cash Flow Sales Ratio | 0.183 | 0.229 | 0.145 | -0.056 | 0.242 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.858 | 0.858 | 0.899 | 1.201 | 0.887 | |
| Debt Service Coverage Ratio | 2.686 | 0.848 | 2.922 | 0.735 | 5.349 | |
| Interest Coverage Ratio | 3.243 | 2.873 | 4.504 | -15.004 | 20.658 | |
| Short Term Operating Cash Flow Coverage Ratio | 5.631 | 7.239 | 4.301 | -1.465 | 6.744 | |
| Operating Cash Flow Coverage Ratio | 0.320 | 0.408 | 0.234 | -0.076 | 0.903 | |
| Capital Expenditure Coverage Ratio | 7.018 | 7.036 | 9.909 | -4.982 | 8.857 | |
| Dividend Paid And Capex Coverage Ratio | 5.220 | 4.049 | 2.357 | -0.622 | 2.217 | |
| Dividend Payout Ratio | 0.064 | 1.503 | 2.622 | -13.298 | 0.350 | |
| Enterprise Value Multiple | 3.201 | 18.172 | 3.866 | 8.954 | 2.357 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 71.5% | ▲0.9% | ▲2.9% |
| Ebit Margin | 25.3% | ▲19.2% | ▲9.2% |
| Ebitda Margin | 27.2% | ▲19.3% | ▲9.8% |
| Operating Profit Margin | 18.5% | ▲2.5% | ▲10.9% |
| Pretax Profit Margin | 19.6% | ▲19.0% | ▲10.6% |
| Continuous Operations Profit Margin | 16.4% | ▲16.4% | ▲8.6% |
| Net Profit Margin | 14.1% | ▲12.5% | ▲6.0% |
| Bottom Line Profit Margin | 14.1% | ▲12.5% | ▲6.0% |
| Current Ratio | 1.215 | ▼-0.107 | ▼-2.016 |
| Quick Ratio | 0.791 | ▼-0.243 | ▼-1.911 |
| Solvency Ratio | 0.194 | ▲0.164 | ▲0.008 |
| Cash Ratio | 0.536 | ▼-0.228 | ▼-1.679 |
| Price To Earnings Ratio | 3.023 | ▼-64.078 | ▼-12.840 |
| Price To Earnings Growth Ratio | 0.004 | ▲2.305 | ▲0.401 |
| Forward Price To Earnings Growth Ratio | 0.004 | ▲2.305 | ▲0.401 |
| Price To Earnings Diluted Ratio | 3.514 | ▼-63.587 | ▼-12.447 |
| Price To Earnings Diluted Growth Ratio | 0.005 | ▲2.307 | ▲0.402 |
| Price To Book Ratio | -1.389 | ▲0.610 | ▼-3.311 |
| Price To Sales Ratio | 0.423 | ▼-0.651 | ▼-0.156 |
| Price To Free Cash Flow Ratio | 2.695 | ▼-2.762 | ▲0.064 |
| Price To Operating Cash Flow Ratio | 2.311 | ▼-2.370 | ▲0.184 |
| Debt To Assets Ratio | 1.022 | ▲0.116 | ▲0.135 |
| Debt To Equity Ratio | -1.878 | ▼-0.831 | ▼-1.780 |
| Debt To Capital Ratio | 2.139 | ▼-20.330 | ▼-3.548 |
| Long Term Debt To Capital Ratio | 2.386 | ▲23.785 | ▲5.404 |
| Financial Leverage Ratio | -1.838 | ▼-0.683 | ▼-2.315 |
| Working Capital Turnover Ratio | 14.622 | ▲11.244 | ▲8.812 |
| Operating Cash Flow Ratio | 0.782 | ▼-0.096 | ▼-0.084 |
| Operating Cash Flow Sales Ratio | 0.183 | ▼-0.046 | ▲0.034 |
| Free Cash Flow Operating Cash Flow Ratio | 0.858 | ▼-0.000 | ▼-0.083 |
| Debt Service Coverage Ratio | 2.686 | ▲1.838 | ▲0.178 |
| Interest Coverage Ratio | 3.243 | ▲0.370 | ▼-0.011 |
| Short Term Operating Cash Flow Coverage Ratio | 5.631 | ▼-1.608 | ▲1.141 |
| Operating Cash Flow Coverage Ratio | 0.320 | ▼-0.088 | ▼-0.038 |
| Capital Expenditure Coverage Ratio | 7.018 | ▼-0.018 | ▲1.450 |
| Dividend Paid And Capex Coverage Ratio | 5.220 | ▲1.171 | ▲2.576 |
| Dividend Payout Ratio | 0.064 | ▼-1.439 | ▲1.816 |
| Enterprise Value Multiple | 3.201 | ▼-14.971 | ▼-4.109 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $81.3M | $211.8M | $127.0M | $30.1M | $74.2M | |
| Enterprise value | $167.1M | $283.3M | $152.9M | $71.3M | $84.8M | |
| EV / Sales | 0.87x | 1.44x | 0.82x | 0.43x | 0.61x | |
| EV / Op. cash flow | 4.75x | 6.26x | 5.69x | -7.78x | 2.52x | |
| EV / Free cash flow | 5.54x | 7.30x | 6.33x | -6.48x | 2.83x | |
| EV / EBITDA | 3.20x | 18.17x | 3.87x | 8.95x | 2.36x | |
| Net debt / EBITDA | 1.64x | 4.59x | 0.65x | 5.18x | 0.29x | |
| Current ratio | 1.22x | 1.32x | 5.51x | 5.39x | 2.72x | |
| Income quality | 1.30x | 983.54x | 8.11x | -6.92x | 1.03x | |
| Graham number | — | — | — | — | $7 | |
| Graham net-net | -$4 | -$5 | -$3 | -$10 | -$2 | |
| Tax burden | 72.0% | 310.7% | -2695.9% | -56.6% | 99.1% | |
| Interest burden | 77.4% | 8.5% | -0.3% | 29.7% | 95.2% | |
| Working capital | $9.7M | $16.6M | $100.1M | $82.4M | $29.8M | |
| Invested capital | $33.2M | $42.0M | $108.2M | $91.0M | $37.0M | |
| Return on assets | 25.1% | 2.6% | 2.1% | -0.9% | 60.0% | |
| Operating ROA | 30.9% | 22.8% | 21.5% | -73.2% | 79.5% | |
| Return on tangible assets | 27.7% | 2.9% | 2.2% | -0.9% | 65.5% | |
| Return on equity | -46.2% | -3.0% | -11.3% | 2.2% | 790.8% | |
| Return on invested capital | 43.0% | 1.8% | 20.5% | -47.3% | 81.1% | |
| Return on capital employed | 56.8% | 44.6% | 21.5% | -65.4% | 93.4% | |
| Earnings yield | 33.3% | 1.5% | 2.6% | -3.2% | 43.9% | |
| Free cash flow yield | 37.1% | 18.3% | 19.0% | -36.6% | 40.3% | |
| Capex / Op. cash flow | 14.2% | 14.2% | 10.1% | -20.1% | 11.3% | |
| Capex / Depreciation | 136.6% | 179.9% | 90.6% | 83.6% | 271.9% | |
| Capex / Sales | 2.6% | 3.3% | 1.5% | 1.1% | 2.7% | |
| SG&A / Sales | 53.0% | 54.5% | 53.3% | 103.7% | 38.7% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 4.6% | 4.4% | 4.9% | 49.8% | 0.0% | |
| Intangibles / Total assets | 9.4% | 12.4% | 3.2% | 4.5% | 8.4% | |
| Days sales outstanding | 15d | 14d | 16d | 15d | 14d | |
| Days payables outstanding | 45d | 36d | 26d | 28d | 33d | |
| Operating cycle | 141d | 107d | 125d | 90d | 86d | |
| Cash conversion cycle | 96d | 71d | 99d | 63d | 53d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-06 biote Corp. (BTMD) Q2 2026 Earnings Call Transcript biote Corp. (BTMD) Q2 2026 Earnings Call Transcript
- 2026-08-05 biote Corp. (BTMD) Reports Break-Even Earnings for Q2 biote Corp. (BTMD) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.03. This compares to earnings of $0.1 per share a year ago.
- 2026-08-05 biote Q2 Earnings Call Highlights biote NASDAQ: BTMD reported lower second-quarter revenue and a net loss as a voluntary recall of certain hormone pellets supplied by Asteria Health disrupted procedure volumes, while management said supply conditions have since normalized and should support sequential improvement in the second half of 2026.
- 2026-08-05 Biote Reports Second Quarter 2026 Financial Results IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners'' patients, today announced financial results for the second quarter ended June 30, 2026. “Over the past year Biote has achieved meaningful progress in advancing our strategic initiatives, driving fundamental improvements that we believe position the Company to achieve sustainable procedure revenue growth,” said Bob Peterso.
- 2026-07-22 Biote Schedules Second Quarter 2026 Financial Results Release and Conference Call IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our Practitioners'' patients, today announced the Company will provide second quarter financial results on Wednesday, August 5, 2026, after the close of the market. A conference call to discuss the firm''s results will be held at 5:00 p.m. ET the same day. Conference Call Details The conference call may be acc.
- 2026-06-01 Biote Appoints Komal Bajaj, MD, MS as Chief Medical Officer IRVING, Texas--(BUSINESS WIRE)--Biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”) today announced the appointment of Komal Bajaj, MD, MS, as Chief Medical Officer, effective June 1, 2026. Dr. Bajaj is a nationally recognized physician executive, board-certified OB/GYN and reproductive geneticist with more than two decades of experience spanning clinical practice, healthcare quality, academic medicine, innovation, and systems leadership. She joins Biote following senior leadership roles with.
- 2026-05-28 Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEO [url="]Biote[/url] (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners'' pa
- 2026-05-28 Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEO IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners'' patients, today announced that Bob Peterson, Chief Financial Officer and Chief Business Officer, has been named Interim Chief Executive Officer and Director, effective June 8, 2026. Bret Christensen is stepping down from his role as Chief Executive Officer and will continue to serve on the Company''s Board of Directors. In.